EUVIMEDEUVIMED entdecken
Kohortenstudie

Clinicopathological characteristics and survival by BRCA status in ovarian cancer: A multicenter retrospective cohort study

Wenna Hu, Zhen Sun, Dehui Zhang, Na Li, Xiao Song, Wei Tian, Ming Liu, Ran Chu, Shuo Zhang

Eurasian Journal of Medicine and Oncology · 03.07.2026 · 026200224

DOI: 10.36922/ejmo026200224 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Eurasian Journal of Medicine and Oncology, online erschienen am 03.07.2026. Verfasst von Wenna Hu und 8 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Breast cancer susceptibility gene 1/2 (BRCA1/2) mutations are implicated in ovarian cancer biology and may influence tumor phenotype, treatment response, and prognosis.

Objective

To compare clinicopathological characteristics and survival outcomes between BRCA-mutated and BRCA wild-type ovarian cancer patients in a multicenter cohort.

Methods

This retrospective cohort study included ovarian cancer patients who underwent BRCA1/2 testing at three hospitals in China from January 2018 to December 2024. Clinicopathological variables were compared between groups. Disease-free survival (DFS) and overall survival (OS) were evaluated using Kaplan–Meier analysis and Cox proportional hazards models.

Results

Among 316 patients, 117 (37.0%) had BRCA mutations and 199 (63.0%) were BRCA wild-type. BRCA-mutated patients had a higher proportion with serous histology (94.9% vs. 87.4%, p = 0.032) and a more frequent use of poly(ADP-ribose) polymerase (PARP) inhibitors (47.9% vs. 20.1%, p < 0.001). They also had lower crude recurrence (49.6% vs. 73.4%, p < 0.001) and mortality rates (28.2% vs. 44.2%, p = 0.006). After adjustment, BRCA mutation status was not independently associated with DFS or OS. Advanced International Federation of Gynecology and Obstetrics (FIGO) stage, neoadjuvant chemotherapy, bilateral tumors, and residual disease > 1 cm were independently associated with shorter DFS, whereas use of a vascular endothelial growth factor inhibitor was associated with longer DFS. Advanced FIGO stage was associated with worse OS, while PARP inhibitor maintenance therapy was associated with longer OS.

Conclusion

BRCA-mutated patients showed better crude outcomes, but the survival difference was attenuated after multivariable Cox adjustment. BRCA testing remains valuable for guiding individualized maintenance therapy.

Zitieren

APA

Hu, W., Sun, Z., Zhang, D., Li, N., Song, X., Tian, W., Liu, M., Chu, R., & Zhang, S. (2026). Clinicopathological characteristics and survival by BRCA status in ovarian cancer: A multicenter retrospective cohort study. Eurasian Journal of Medicine and Oncology, 0(0), 026200224. https://doi.org/10.36922/ejmo026200224

Vancouver

Hu W, Sun Z, Zhang D, Li N, Song X, Tian W, et al. Clinicopathological characteristics and survival by BRCA status in ovarian cancer: A multicenter retrospective cohort study. Eurasian Journal of Medicine and Oncology. 2026;0(0):026200224. doi:10.36922/ejmo026200224

BibTeX
@article{Hu2026,
  author = {Hu, Wenna and Sun, Zhen and Zhang, Dehui and Li, Na and Song, Xiao and Tian, Wei and Liu, Ming and Chu, Ran and Zhang, Shuo},
  title = {Clinicopathological characteristics and survival by BRCA status in ovarian cancer: A multicenter retrospective cohort study},
  journal = {Eurasian Journal of Medicine and Oncology},
  year = {2026},
  volume = {0},
  number = {0},
  pages = {026200224},
  doi = {10.36922/ejmo026200224}
}
Kostenlos starten →